Adenovirus vectors containing cell status-specific response...

Details Adenovirus vectors containing cell status-specific response... Adenovirus vectors containing cell status-specific response...

2004-09-09

2009-08-18

Whiteman, Brian (Department: 1635)

Chemistry: molecular biology and microbiology

Vector, per se

Reexamination Certificate

active

07575919

ABSTRACT:
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.

REFERENCES:
patent: 5648478 (1997-07-01), Henderson
patent: 5677178 (1997-10-01), McCormick
patent: 5698443 (1997-12-01), Henderson
patent: 5770442 (1998-06-01), Wickham
patent: 5801029 (1998-09-01), McCormick
patent: 5830686 (1998-11-01), Henderson
patent: 5834306 (1998-11-01), Webster et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5994128 (1999-11-01), Fallaux
patent: 5998205 (1999-12-01), Hallenbeck
patent: 6057299 (2000-05-01), Henderson
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 6432700 (2002-08-01), Henderson
patent: 6436394 (2002-08-01), Henderson
patent: 6495130 (2002-12-01), Henderson
patent: 6551587 (2003-04-01), Hallenbeck
patent: 6585968 (2003-07-01), Little
patent: 6627190 (2003-09-01), Wold et al.
patent: 6638762 (2003-10-01), Chang
patent: 6676935 (2004-01-01), Henderson
patent: 6692736 (2004-02-01), Yu et al.
patent: 6777203 (2004-08-01), Morin
patent: 6852528 (2005-02-01), Yu et al.
patent: 6900049 (2005-05-01), Yu et al.
patent: 6916918 (2005-07-01), Yu et al.
patent: 6991935 (2006-01-01), Henderson et al.
patent: 7078030 (2006-07-01), Johnson et al.
patent: 7319033 (2008-01-01), Henderson et al.
patent: 7396679 (2008-07-01), Johnson et al.
patent: 7482156 (2009-01-01), Arroyo et al.
patent: 2001/0053352 (2001-12-01), Yu
patent: 2001/0053768 (2001-12-01), Gregory et al.
patent: 2002/0120117 (2002-08-01), Zhang
patent: 2002/0136707 (2002-09-01), Yu
patent: 2002/0192187 (2002-12-01), McClelland
patent: 2003/0026792 (2003-02-01), Lamparsky
patent: 2003/0039633 (2003-02-01), Yu
patent: 2003/0068307 (2003-04-01), Yu
patent: 2003/0095989 (2003-05-01), Irving et al.
patent: 2003/0104625 (2003-06-01), Cheng/Ennist
patent: 2003/0152553 (2003-08-01), Henderson
patent: 2004/0175364 (2004-09-01), McClelland et al.
patent: 2005/0095705 (2005-05-01), Kadan et al.
patent: 2005/0169890 (2005-08-01), Yu et al.
patent: 0845537 (1998-06-01), None
patent: 1147181 (2000-08-01), None
patent: WO 92/03563 (1992-03-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 03/007859 (2003-01-01), None
patent: WO 03/104476 (2003-12-01), None
patent: WO 2004/042025 (2004-05-01), None
Ryan et al. Cancer Gene Therapy, 10, Supplement 1, pp. S14, Meeting Info: Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, USA, 2003.
Ryan et al. (Cancer Gene Therapy, 2004 11, 555-569.
Abe et al. (1993). “Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma Associated Antigin (MUCI) Gene,”Proc. Natl. Sci. USA90:282-286.
Arnberg et al. (1997). “Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract,”Virol. 227:239-244.
Ausubel et al. eds. (1987).Current Protocols In Molecular Biology Suppl. 30 Sec. 7.7.18, Table 7.7.1.
Bailey et al. (1993). “Enteric Adenovirus Type 40: Expression of E1B Proteins in Vitro and in Vivo,”Virol. 193:631-641.
Bailey et al. (1994). “Cell Type Specific Regulation of Expression from the Ad40 E1B Promoter in Recombinant Ad5/Ad40 Viruses,”Virol. 202: 695-706.
Behringer et al. (1988). “Dwarf Mice Produced by Genetic Ablation of Growth Hormone-Expressing Cells,”Genes Dev, 2: 453-461.
Berkner et al. (1983). “Generation of Adenovirus by Transfection of Plasmids,”Nuc. Acid Res. 11(17): 6003-6020.
Bett et al. (1993). “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”J. Virol. 67(10):5911-5921.
Bett et al. (1994). “An efficient and Flexible System for Construction of Adenovirus Vectors with Insertions or Deletions in Early Regions I and 3,”Proc. Natl. Acad. Sci. USA91: 8802-8806.
Bridge et al. (1989). “Rodundant Control of Adenovirus Late Gene Expression by Early Region 4,”J. Virol. 63(2): 631-638.
Bunn et al. (1996). “Oxygen Sensing and Molecular Adaptation to Hypoxia,”Physiol. Rev. 76(3):839-885.
Cannio et al. (1991). “A Cell-Type Specific and Enhancer-Dependent Silencer in the Regulation of the Expression of the Human Urokinase Plasminogen Activator Gene,”Nuc. Acids Res. 19(9):2303-2308.
Colditz. (1993). “Epidemiology of Breast Cancer,”Cancer Suppl. 71(4): 1480-1489.
Dachs et al. (1996). “The Molecular Response of Mammalian Cells to Hypoxia and the Potential for Exploitation in Cancer Therapy,”Br. J. Cancer14: 5126-5132.
Dachs et al. (1997). “Targeting Gene Expression to Hypoxic Tumor Cells,”Nat. Med. 3(5): 515-520.
Feigner et al. (1989), “Cationic Liposome-Mediated Transfection,”Nature337:387-388.
Firth et al. (1994). “Oxygen-Related Control Elements in the Phosphoglycerate Kinase I and Lactate Dehydrogenase A Genes: Similarities with the Erythropoietin 3′Enhancer,”Proc. Natl. Acad. Sci. USA91: 6496-6500.
Flint. (1982). “Expression of Adenoviral Genetic Information in Productively Infected Cells,”Biochem. Biophys. Acta651: 175-208.
Flint. (1986). “Regulation of Adenovirus mRNA Formation,”Adv. Vir. Res. 31: 169-228.
Folkman. (1989). “What is the Evidence that Tumors are Angiogenesis Dependent?”J. Natl. CancerInst. 82(1):4-6.
Frankel et al. (1989). “Selection and Characterization of Ricin Toxin A-Chain Mutations inSaccharomyces cerevislae,” Mol. Cell. Biol. 9(2): 415-420.
Graham. (1984). “Covalently Closed Circles of Human Adenovirus DNA are Infectious,”EMBOJ. 3(12):2917-2922.
Grand. (1987). “The Structure and Functions of the Adenovirus Early Region I Proteins,”Biochem. J. 241:25-38.
Grooteclaes et al. (1984). “The 6-Kilobasec-erbB2Promoter Contains Positive and Negative Regulatory Elements Functional in Human Mammary Cell Lines,”Cancer Res. 54: 4193-4199.
Guillemin et al. (1997). “The Hypoxic Response: Huffing and HIFing,”Cell89: 9-12.
Hallahan et al. (1995), “Spatial and Temporal Control of Gene Therapy Using Ionizing Radiation,”Nat. Med. 1(8): 786-791.
Hockel et al. (1996). “Hypoxia and Radiation Response in Human Tumors,”Semin. Rad. Oncol. 6(1): 3-9.
Hudson et al. (1990), “Structure and Inducible Regulation of the Human c-erbBZ
euPromoter,”J. Biol. Chem. 265: 4389-4393.
Ido et al. (1995). “Gene Therapy for Hepatoma Cells Using a Retrovirus Vector Carrying Herpes Simplex Virus Thymidine Kinase Gene Under the Control of Human a-Fetoprotein Gene Promoter,”Cancer Res. 55:3105-3109.
Ishii et al. (1987). “Characterization of the Promoter Region of the HumanC-erb B-2Protooncogene,”Proc. Natl. Acad. Sci. USA84: 4374-4378.
Jiang et al. (1997), “V-SRC Induces Expression of Hypoxia-inducible Factor I (HIF-1) and Transcription of Genes Encodin

Affiliated with

Also associated with

Rating

Adenovirus vectors containing cell status-specific response... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adenovirus vectors containing cell status-specific response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors containing cell status-specific response... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4071301